Elmind Capital LP Acquires Shares of 525,750 Pharvaris N.V. $PHVS

Elmind Capital LP acquired a new position in Pharvaris N.V. (NASDAQ:PHVS) during the second quarter, Holdings Channel.com reports. The firm acquired 525,750 shares of the company’s stock, valued at approximately $18,180,435,000. Pharvaris comprises 4.6% of Elmind Capital LP’s holdings, making the stock its 7th biggest holding.

Several other hedge funds also recently added to or reduced their stakes in PHVS. California State Teachers Retirement System raised its position in Pharvaris by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after acquiring an additional 520 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Pharvaris in the 2nd quarter valued at $41,000. Public Employees Retirement System of Ohio boosted its holdings in Pharvaris by 20.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after buying an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Citizens Jmp increased their target price on shares of Pharvaris from $74.00 to $75.00 and gave the stock a “market outperform” rating in a research note on Thursday, August 13th. Royal Bank Of Canada boosted their price target on shares of Pharvaris from $51.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. New Street Research set a $60.00 target price on shares of Pharvaris in a research report on Friday, August 14th. UBS Group set a $74.00 price target on shares of Pharvaris in a research report on Wednesday, May 13th. Finally, Wells Fargo & Company began coverage on Pharvaris in a report on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $51.08.

Pharvaris Trading Down 0.2%

PHVS opened at $37.23 on Wednesday. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $38.13. The firm has a market capitalization of $2.44 billion, a PE ratio of -12.21 and a beta of -2.31. The firm’s 50-day moving average price is $34.40 and its 200 day moving average price is $30.56.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, analysts predict that Pharvaris N.V. will post -3.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Pharvaris news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the transaction, the director owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. The trade was a 8.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Berndt Modig sold 2,292 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $34.77, for a total value of $79,692.84. Following the completion of the sale, the chief executive officer directly owned 130,625 shares of the company’s stock, valued at $4,541,831.25. This trade represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 121,325 shares of company stock worth $4,270,425.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.